You are adding an alert for:
Preliminary results from the RESPOND trial: Investigator-driven study in Portugal to evaluate real-life safety and efficacy of ILUVIEN in patients with chronic DME.
You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
The alert will be sent to: